PARP Inhibition: “Targeted” Therapy for Triple Negative Breast Cancer

In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating advanced triple negative breast cancer (TNBC) are lacking. PARP (Poly-(adenosine diphosphate [ADP]-ribose) polymerase) inhibitors are emerging as one of the most promising ‘targeted’ therapeutics to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Anders, Carey K., Winer, Eric P., Ford, James M., Dent, Rebecca, Silver, Daniel P., Sledge, George W., Carey, Lisa A.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2948607/
https://ncbi.nlm.nih.gov/pubmed/20858840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0939
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items